Evolution in the treatment landscape of non-small cell lung cancer with ALK gene alterations: from the first- to third-generation of ALK inhibitors
Author:
Affiliation:
1. Division of Medical Oncology, ‘S. G. Moscati’ Hospital, Avellino, Italy
Funder
not funded
Publisher
Informa UK Limited
Subject
Pharmacology (medical),Pharmacology
Link
https://www.tandfonline.com/doi/pdf/10.1080/14728214.2018.1527902
Reference96 articles.
1. Cancer statistics, 2017
2. The anaplastic lymphoma kinase in the pathogenesis of cancer
3. Molecular characterization of ALK, a receptor tyrosine kinase expressed specifically in the nervous system
4. Cell Signaling by Receptor Tyrosine Kinases
5. Anaplastic lymphoma kinase: signalling in development and disease
Cited by 28 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Natural product-derived ALK inhibitors for treating ALK-driven lung cancers: an in silico study;Molecular Diversity;2024-08-08
2. Small Molecule Tyrosine Kinase Inhibitors (TKIs) for Glioblastoma Treatment;International Journal of Molecular Sciences;2024-01-23
3. Treatment of advanced ALK-rearranged NSCLC following second-generation ALK–TKI failure;Expert Review of Anticancer Therapy;2023-10-05
4. Inhibition of HSP90 in Driver Oncogene-Defined Lung Adenocarcinoma Cell Lines: Key Proteins Underpinning Therapeutic Efficacy;International Journal of Molecular Sciences;2023-09-07
5. The role of genetic testing in the prognosis and management of solid tumors. A literature review;Revista Romana de Medicina de Laborator;2023-07-01
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3